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Summary
Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor a
(TNF-a) when these cells are triggered with lipopolysaccharide and other agonists in culture.
40% inhibition occurs at the clinically achievable dose of the drug of 1 Ag/ml . In contrast, the
amount of total protein and individual proteins labeled with [31S]methionine and expressed on
SDS-PAGE are not influenced . The amounts of interleukin 10 (11,1(3), Ilr6, and granulocyte/
macrophage colony-stimulating factor produced by monorytes remain unaltered . The selectivity
of this drug may be useful in determining the role of TNF-a in vivo and modulating its toxic
effects in a clinical setting.
T
halidomide (a-N-pthalimidoglutarimide) has a long phar-
macological history, having been used as a sedative, an
antiinflammatory, and an immunosuppressive agent (1-3) .
Currently, it is used for the therapy of erythema nodosum
leprosum (ENL),' or type II reaction, an acute inflamma-
tory state occurring in lepromatous leprosy characterized by
severe systemic symptoms, including fever, painful cutaneous
lesions, arthritis, glomerulonephritis, and the presence of cir-
culatingimmune complexes (4) . In this serious complication
of leprosy, thalidomide has a prompt and dramatic effect,
decreasing inflammation and enhancing patient well-being
so that it remains the drug of choice for the therapy ofENL
(5) . The fever, weight loss, and general debility ofENL, as
in other forms of acute and chronic disease, including sepsis
and cancer, may be associated with the production of macro-
phage-derived cytokines (6, 7) . Recently, serum levels of
TNF-a and 11,1/3 released mainly by mononuclear phago-
cytes were found to be markedly elevated in ENL (8) . In ad-
dition, it was noted that TNF-a levels were reduced after
treatment of patients in ENL . This prompted a detailed ex-
amination of the effects of thalidomide on cytokine produc-
tion by monorytes .
'Abbreviations used in this paper . CWRML, cell wall protein of Mpco-
bacteriumkp ae ; ENL, erythema nodosum leprosum ; GM-CSF, granulocyte/
macrophage colony-stimulating factor; PPD, purified protein derivative
of tuberculin.
Materials and Methods
Monocyte Isolation.
￿
PBMC obtained by Ficoll-Hypaque (Phar-
macia Fine Chemicals, Piscataway, NJ) density centrifugation were
rosetted with neuraminidase-treated (Vibrio cholerae neuraminidase;
Calbiochem-Behring Corp., LaJolla, CA) sheep erythrocytes (Scott
Laboratories, Friskville, RI) (SRBC rosetting), and the nonrosetted
cells were counted (E - population monorytes enriched) . 106 cells
were cultured at 37°C in 24-well plates (Coming Glass Works,
Coming, NY) in 1 ml ofRPMI 1640 (Gibco Laboratories, Grand
Island, NY) supplemented with 10% AB* serum, 100 U/ml pen-
icillin, 100 Etg/ml streptomycin, and 2MM L-glutamine. Adherent
E - cells were used for the studies .
Cytokine Agonists.
￿
LPS ofSalmonella minnesota R595 (List Bio-
logical Laboratories, Campbell, CA) was diluted in PBS, pH 7.4,
and used at 1 wg/ml; Purified protein derivative of tuberculin (PPD)
was purchased from Statens Seruminstitut, Copenhagen, Denmark;
cell wall protein of Mycobacterium leprae (CWP-ML) was prepared
through the National Institute ofAllergy and Infectious Diseases,
and provided by Dr. Patrick Brennan (Department ofMicrobiology,
Colorado State University, Fort Collins, CO) . Concentration of
the stimulating agents were determined in previous experiments
to induce optimal TNF-tx protein production by cultured mono-
cytes . The endotoxin content of solutions and mycobacterial prepa-
rations was estimated by the Limulus amebocyte lysate assay (LAL;
Whittaker M.A . Bioproducts, Walkersville, MD) . All solutions
used contained <10 pg/ml of endotoxin .
Cytokine Induction . Adherent E- cells were stimulated with
1 hg/ml of LPS, 10 Rg/ml of PPD, or 10 Wg/ml ofCWP-ML for
up to 18-20 h . At various times, supernatants were harvested, cen-
trifuged to remove cells and debris, and kept frozen until use
(-20°C) .
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￿
TNF-a concentration in the supernatants was
determined with aTNF-a-specific ELISA, specific forthebiologi-
cally active molecule. Thereagents were adonation from Dr. Baron
R. Reed, Genentech, Inc., South San Francisco, CA. Assays were
performedin 96-well plates (NuncImmunoplates, Roskilde,Den-
mark)coated with theaffinity-purified rabbit antiTNF-a antibody
(0.5 ug/ml; 12-16 h; 4°C) andblocked for 2 h at room tempera-
ture with PBS/0.05% Tween 20 (Sigma Chemical Co., St. Louis,
MO) containing 5 mg/ml BSA. Afterwashing, 100 P,1of TNF-a
standards, samples, andcontrols were applied to the wells, and the
plates were incubated for 12-24 h at 4°C. After the incubation,
plates were washed and a second antibody, horseradish peroxidase
(HRP)-conjugated mousemonoclonal antiTNF-ac,diluted 1:2,000
in PBS/BSA/Tween, was applied to the wells and incubated for
2 h at room temperature. The color reaction was developed with
theOPD substrate(0.4 mg/mlo-phenylenediamine [Sigma Chem-
ical Co.] in 24 mM citric acid, 51 mM sodium phosphate, pH 5.0
[phosphate-citrate buffer; SigmaChemical Co.], containing 0.012%
hydrogen peroxide [H202; Fisher Scientific Co., Pittsburgh, PA])
andabsorbance read at 492nm in an automatedELISAreader (Dy-
natech Laboratories, Inc., Alexandria, VA).
ILIl Assays.
￿
IMOlevels were determined using acommercial
ELISA kit (Cistron Biotechnology, Pine Brook, NJ) accordingto
the manufacturer's specifications. 11,10levels areexpressedas pico-
grams per milliliter of protein.
IL6Assay.
￿
11,6 levels were determined using abiological assay
as described(9). Proliferationof7TD1 hybridomacellline specifically
sensitive to IL6 was measured by colorimetric determination of
hexosaminidase levels (10), and values for IL6 in the samples were
obtained by interpolation from a standard curve. 1 U/ml of IL6
corresponds to theconcentration that yields half-maximal growth.
Granulocyte/Macrophage CSF(GM-CSF) Assay.
￿
GM-CSF levels
were determined using a commercial ELISAkit (Genzyme, Boston,
MA) according to the manufacturer's specifications, and were ex-
pressed as picograms per milliliter of protein.
Thalidomide Inhibition.
￿
Thethalidomide used in this studywas
the purified drug (racemic mixture of D [+] and L [-] forms)
(lot No.JB-I-114; Andrulis Research Corporation, Beltsville, MD).
Thecompound was shownto be at least99% pure,meltingsharply
at 270°C (published melting range, 269-271°C) (11). It was then
diluted in DMSO (Sigma Chemical Co.); further dilutions were
done in sterile PBS.
Percentage inhibition ofTNFa secretion wascalculated as: 100x
[1-(TNF-a experimental/TNF-ca control)]; where TNF-a ex-
perimental represents TNF-ca secretion by stimulated monocytes
that were cultured in the presence ofthalidomide, andTNF-acon-
trol represents TNF-ca secretion by stimulated monorytesthat were
cultured in theabsence of thedrug.Monocytescultured in medium
containing equivalent amounts of DMSO in the presence or ab-
senceofthe stimulating agentwere used as controls for thalidomide-
treated cells. Neither thalidomide nor DMSO had any effect on
cell viability or function at the concentrations used.
Protein Synthesis.
￿
Human monocytes were cultured in teflon
beakers in methionine-free RPMI with 10% AB* serum at 37°C
for 1 h, when 200 pCi/ml [35S]methionine (1,153 Ci/mmol; ICN
Biomedicals Inc., Irvine, CA) was added to the cultures for the
next 3 h with or without thestimulating andthesuppressive agent.
At the end of the labeling period, 35S-labeled cells were washed
twice in ice-cold PBS and lysed directly in 500 P1 lysis solution
(10 mM Tris-HCI buffer, pH 7.4, 150 NaCl, 1 mM EDTA, and
1% SDS). Resolving8% SDS-PAGE wasperformedovernight.The
gel waswashed,dried, andanalyzed by autoradiography at -70°C
usingXAR-5radiographic film (Kodak, Rochester, NY)with an
intensifying screen.
Results
Monocytes were enriched from PBMC of normal donors
and stimulated in vitro for 18-20 h with bacterial LPS and
mycobacterial products, known agonists ofmonocyte TNF-a
synthesis and secretion (12, 13). Thalidomide suppressed LPS-
stimulated TNF-ci production (Fig. 1 A) with a 50% in-
hibitory concentration (IC5o) of 1-4 P,g/ml, and -90%
inhibition observed at 10 dug/ml (18-20-h assay). Similar results
were obtained when PPD and CWRML were used as stimu-
lants (Fig. 1, B and C, respectively).
The inhibition of TNF-a secretion by thalidomide was
dependent upon the stateof monocyte stimulation (Table 1).
Preincubation of unstimulated monocytes with thalidomide,
followed by removal of the drug before LPS stimulation, did
not lead to suppression. By comparison, when LPS and
thalidomide were added simultaneously to the cultures, irre-
versible suppression occurred, even when the drug was re-
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Figure 1. Effect of thalidomide on (A) bacterial endotoxin (LPS,
1 jig/ml), (B) PPD, (10 pg/ml), and (C) CWP-ML (10 Wg/ml)-induced
TNF-aproduction. Monocyteswere simultaneouslyincubatedwith 2ng/ml
to 10 Ftg/ml of thalidomide in the culture medium. Control cells were
cultured in medium alone.A dose-dependent inhibition of TNF-a secre-
tion by thalidomide was noted. No detectable production of TNF-apro-
tein wasobserved in supernatants ofunstimulated monocytes. Data repre-
sent mean ± SD of 15 (A), two (B), and one (C)differentexperiments,
respectively.Table 1 .
￿
Effect ofPreincubation ofMonocytes with Thalidomide
Human monocytes cultured in 24-well plates were preincubated with the inhibitory drug with or without the stimulating agent . After 4 h, the
cultures were washed, medium was replaced, andLPS was added again for the next 16 h. Culture supernatants were recovered at the different periods
and TNF-a levels determined as described. LPS-induced release of TNF-a by monocytes cultured for 20 h in the absence of thalidomide (A) . No
inhibitory action of thalidomide was detected when the drug was washed away before the addition of the stimulating agent (B) . Thalidomide-induced
inhibition of TNF-a production in the presence of LPS after 4 h of stimulation (C), which perisisted even after the drug was washed away (D) .
Control experiment in which thalidomide was kept in the cultures with the stimulating agent during the whole assay (E) . Data represent mean
± SD of two different experiments .
Figure 2 .
￿
Effect of thalidomide on protein synthesis by human periph-
eral blood monocytes. Electrophoretic analysis of lysates from monocytes
incubated with [35S]methionine was performed. Cells were stimulated in
vitro with and without LPS in the presence or absence of thalodomide
at 1 and 4 Wg/ml . TCA-precipitable radioactivity (10% TCA precipita-
tion) was measured byliquid scintillation counting.Theamount ofradio-
activity in the pellets is expressed as cpm . x 10- 3 and represents the mean
of three precipitates with a SD of 10%. Neither total radioactivity nor
the pattern ofmost ofthe proteinbands in the gel was affected by thalido-
mide. (Lane 1) Unstimulated cells, 3.3 x 10-2 cpm . in TCA precipitates ;
(lane 2) cells stimulated with 1 ug/ml LPS, 4.2 x 10 -2 cpm in TCA
precipitate ; (lane 3) cells stimulated with LPS in the presence of 1 Fag/ml
thalidomide, 4.2 x 10 -2 cpm in TCA precipitate ; (lane 4) cells stimu-
lated with LPS in the presence of4 pg/ml thalidomide, 4.1 x 10-2cpm
inTCA precipitate; (lanes Sand 6) cells incubated only with thalidomide
at 1 or 4 F+g/ml, respectively, 3.2 x 10 -2 and2.8 x 10-2 cpm in TCA
precipitates, respectively.
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moved after afewhours (Table 1) . Therefore, the thalidomide-
sensitive reaction(s) occurs only after the LPS induction of
TNF-a production .
The inhibition of LPS-stimulated TNF-a secretion by
thalidomide occurs in a setting in which many other pro-
teins arebeing synthesizedby both constitutive and induced
mechanisms (14) . Thus, a simple explanation for the effect
of the drug on TNF-a production could be a suppression
of overall protein synthesis . Fig. 2 illustrates the effect of
thalidomide on the pattern and quantity of proteins synthe-
Figure 3.
￿
Levels of different cytokines tested in culture supernatants of
human monocytes stimulated with LPS for6 h (A-C) or 20 h (D) in the
presence or absence of4 or 10 P,g/ml ofthalidomide. Data represent mean
± SD of six different experiments forTNF-aand IL1fl determinations
and three experiments for IL6 andGM-CSF measurements. About 41 .9
± 14.6% and 52 .8 t 14.7% inhibition of TNF-a secretion was found
in the presence of 4 and 10 FAg/ml of thalidomide, respectively. (Coot)
Unstimulated cells cultured in medium . No effect on 11,119, I1r6, orGM-
CSF secretion was detected in these cultures.
Time
Preincubation
Thalidomide
(4 hg/ml)
LPS
(1 Wg/ml) Time
Incubation
Thalidomide
(4 gg/ml)
LPS
(1 Ag/ml)
Percent
activity
h h
A 0-4 0 0 4-20 0 + 100
B 0-4 + 0 4-20 0 + 90 ± 4.6
C None 0 0 0-4 + + 48 ± 15
D 0-4 + + 4-20 0 + 56 ± 0.5
E None 0 0 0-20 + + 52 ± 9.3sized after a 3-h pulse of [35S]methionine (legend to Fig . 2) .
The total incorporation of isotope into TCAprecipitable pro-
teins as well as the intensity of most of the individual bands
on SDS-PAGE of LPS-triggered monocytes remained un-
changed after thalidomide treatment .
Several cytokines are produced by monocytes in response
to LPS in addition to TNF-ci, including IW/3 and IM (15-16) .
Fig . 3 shows that thalidomide exerts a selective effect by sup-
pressing only TNF-ot secretionby LPS-stimulated monocytes .
Whereas 4 /Ag/ml thalidomide suppressed TNF-ci produc-
tion (41.9% inhibition) (Fig. 3 A), neither 1140 (Fig. 3 B),
IM (Fig. 3 C), nor GM-CSF production (Fig. 3 D) was
influenced by the drug. Similar but more extensive selective
suppression was observed withmuch higher (up to 20 ug/ml)
concentrations of thalidomide (not shown) .
Discussion
These experiments demonstrate that thalidomide inhibits
TNF-a production by human blood monocytes, without
influencing either general protein synthesis or the expression
of three other monocyte-derived cytokines . Although cells
of the mononuclear phagocyte series appear to be the major
producers of TNF-ci, other cells, in particular, T lympho-
cytes and NK cells, also synthesize this molecule. Therefore,
additional experiments clarifying the spectrum of cell types
sensitive to thalidomide action are now warranted. Experi-
ments in animals and clinical observations in various inflam-
matory diseases (17-19) suggest that the production of excess
TNF-ot is related to a number of toxic manifestations of in-
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